abrdn plc Buys Shares of 200,000 TScan Therapeutics, Inc. (NASDAQ:TCRX)

abrdn plc bought a new stake in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 200,000 shares of the company’s stock, valued at approximately $1,166,000. abrdn plc owned about 0.42% of TScan Therapeutics at the end of the most recent quarter.

Separately, Pale Fire Capital SE acquired a new position in TScan Therapeutics during the 3rd quarter worth $42,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a research note on Thursday, March 7th. Wedbush reiterated an “outperform” rating and issued a $10.00 target price on shares of TScan Therapeutics in a research report on Tuesday, April 23rd.

TScan Therapeutics Stock Up 4.9 %

Shares of NASDAQ:TCRX opened at $7.68 on Tuesday. TScan Therapeutics, Inc. has a 1-year low of $1.62 and a 1-year high of $9.00. The company’s fifty day moving average is $7.20 and its two-hundred day moving average is $5.88. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.51 and a current ratio of 6.51. The stock has a market capitalization of $367.72 million, a price-to-earnings ratio of -4.06 and a beta of 0.90.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Wednesday, March 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. The firm had revenue of $7.21 million for the quarter, compared to analysts’ expectations of $2.94 million. TScan Therapeutics had a negative net margin of 423.86% and a negative return on equity of 60.65%. Equities analysts anticipate that TScan Therapeutics, Inc. will post -1.03 EPS for the current year.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.